Eiger BioPharmaceuticals Inc

NASDAQ:EIGR  
9.24
+0.49 (+5.60%)
Products

Eiger Biopharmaceuticals Announces FDA Approval Of Zokinvy

Published: 11/20/2020 23:03 GMT
Eiger BioPharmaceuticals Inc (EIGR) - Eiger Biopharmaceuticals Announces FDA Approval of Zokinvy™ (lonafarnib): the First Treatment for Hutchinson-gilford Progeria Syndrome and Processing-deficient Progeroid Laminopathies.
Eiger Biopharmaceuticals - Plans to Sell Prv and Under Terms of Agreement With Progeria Research Foundation (prf) Will Share Proceeds Equally With Prf.